Vireo Growth Inc · CSE:VREO
Vireo Growth — Vireo Health International — Q4 2020 Earnings Presentation
13 slides from Vireo Growth's earnings presentation, Mar 25, 2021
Slide 1: Q4 2020 Earnings Conference Call
“We are building the cannabis company of the future by bringing the best of science, medicine and engineering to the cannabis industry.” Q4 2020 Earnings Conference Call March 25, 2021 - Kyle Kingsley, M.D. CSE: VREO OTCQX: VREOF Founder & CEO
Slide 2: Disclaimer
Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This document includes information, statements, beliefs and opinions which are forward-looking, and which reflect current estimates, expectations and projections about future events, referred to herein and which constitute “forward-lo
Slide 3: Today's Presenters
Today’s Presenters Kyle Kingsley, M.D. Chairman & Chief Executive Officer Dial-in & Webcast Details: Conference Call Registration: John Heller http://www.directeventreg.com/registration/ Chief Financial Officer event/7871948 Webcast Registration: https://event.on24.com/wcc/r/2947732/7426 Sam Gibbons
Slide 4: Full Year 2020 Highlights
Full Year 2020 Highlights • Total revenue of $49.2 million increased 64.3 percent YoY, driven by organic growth and the successful execution of management’s core market strategies during the year. • Gross profit increased by $9.8 million to $17.1 million, or 34.8 percent of sales as compared to $7.3
Slide 5: Key Fourth Quarter and Full Year 2020 Financial Metrics
Key Fourth Quarter and Full Year 2020 Financial Metrics Summary of Key Financial Metrics Three Months Ended Twelve Months Ended December 31, December 31, US $ in millions 2020 2019 Variance 2020 2019 Variance GAAP Revenue $12.4 $9.0 38% $49.2 $30.0 64% Revenue (excl. former Pennsylvania subsidiaries
Slide 6: Fiscal Year 2020 Performance
Fiscal Year 2020 Performance • Total GAAP revenue increased 64.3 percent year-over- year, driven by organic growth across all of Vireo’s operational markets and the successful execution of management’s core market strategies. • Excluding results from the Company’s former subsidiaries in Pennsylvania
Slide 7: Fourth Quarter 2020 Performance
Fourth Quarter 2020 Performance • Total GAAP revenue of $12.4 million increased 38 percent year-over-year, driven by organic growth across all of Vireo’s operational markets and the successful execution of management’s core market strategies. • Excluding results from the Company’s former subsidiarie
Slide 8: Slide 8
Slide 9: Consolidated Balance Sheets as of December 31, 2020 and 2019
VIREO HEALTH INTERNATIONAL, INC. Consolidated Balance Sheets as of CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2020 AND 2019 (Amounts Expressed in United States Dollars, Except for Share Amounts) December 31, 2020 December 31, 2019 December 31, 2020 and 2019 Assets Current assets: Cash $ 25,513,1
Slide 10: Consolidated Statements of Operations Years Ended December 31, 2020 and 2019
VIREO HEALTH INTERNATIONAL, INC. Consolidated Statements of Operations CONSOLIDATED STATEMENTS OF OPERATIONS Years Ended December 31, 2020 and 2019 YEARS ENDED DECEMBER 31, 2020 AND 2019 (Amounts Expressed in United States Dollars, Except for Share Amounts) December 31, 2020 December 31, 2019 Revenu
Slide 11: Consolidated Statements of Operations 3-Months Ended December 31, 2020 and 2019
VIREO HEALTH INTERNATIONAL, INC. Consolidated Statements of Operations CONSOLIDATED STATEMENTS OF OPERATIONS THREE MONTHS ENDED DECEMBER 31, 2020 AND 2019 3-Months Ended December 31, 2020 and 2019 (Amounts Expressed in United States Dollars, Except for Share Amounts) Q4 2020 Q4 2019 Revenue $ 12,401
Slide 12: Consolidated Statements of Cash Flows Years Ended December 31, 2020 and 2019
VIREO HEALTH INTERNATIONAL, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS Consolidated Statements of Cash Flows YEARS ENDED DECEMBER 31, 2020 AND 2019 (Amounts Expressed in United States Dollars, Except for Share Amounts) December 31, 2020 December 31, 2019 Years Ended December 31, 2020 and 2019 CASH F
Slide 13: Reconciliation of Non-GAAP to GAAP Financial Measures
Reconciliation of Non-GAAP to GAAP Financial Measures Three Months Ended Twelve Months Ended December 31, December 31, 2020 2019 2020 2019 Net income (loss) $ (2,265,842) $ (39,494,314) $ (22,942,194) $ (57,479,312) Interest expense, net 846,758 1,628,867 5,095,848 4,460,331 Income taxes 1,990,000 (
Vireo Health International — Q4 2020 Earnings Presentation on 6ix